Literature summary for 3.5.1.88 extracted from

O'Dwyer, K.; Hackel, M.; Hightower, S.; Hoban, D.; Bouchillon, S.; Qin, D.; Aubart, K.; Zalacain, M.; Butler, D.
Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322 (2013), Antimicrob. Agents Chemother., 57, 2333-2342.

Search for more literature for 3.5.1.88

Inhibitors

Inhibitors	Comment	Organism	Structure
(2R)-N-[(2S)-1-{4-[(2H-1,3-benzodioxol-5-yl)methyl]piperazin-1-yl}-3,3-dimethyl-1-oxobutan-2-yl]-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanamide	-	Moraxella catarrhalis
actinonin	-	Moraxella catarrhalis
GSK1322322	an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview	Haemophilus influenzae
GSK1322322	an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview	Staphylococcus aureus
GSK1322322	an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview	Streptococcus pyogenes
GSK1322322	an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview	Streptomyces pneumoniae
N-(5-fluoro-1-hydroxypyridin-1-ium-2-yl)-1-[(2R)-2-[[formyl(hydroxy)amino]methyl]hexanoyl]prolinamide	-	Moraxella catarrhalis
N-[(2R)-2-(cyclopentylmethyl)-3-(2-{5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methylpyrimidin-4-yl}hydrazinyl)-3-oxopropyl]-N-hydroxyformamide	an enzyme inhibitor being developed for the intravenous and oral treatment of acute bacterial skin and skin structure infections of humans and hospitalized patients with community-acquired pneumonia. The compound shows good antibacterial activity against common RTI and SSSI pathogens, overview	Moraxella catarrhalis

Organism

Organism	UniProt	Comment	Textmining
Haemophilus influenzae	-	-	-
Moraxella catarrhalis	-	-	-
Staphylococcus aureus	-	-	-
Streptococcus pyogenes	-	-	-
Streptomyces pneumoniae	-	-	-

Synonyms

Synonyms	Comment	Organism
peptide deformylase	-	Staphylococcus aureus
peptide deformylase	-	Haemophilus influenzae
peptide deformylase	-	Streptococcus pyogenes
peptide deformylase	-	Moraxella catarrhalis
peptide deformylase	-	Streptomyces pneumoniae

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)